[1]刘晓鑫,白春峡,伏　玉.乳腺癌组织MAL2和IGF-1R蛋白表达与病理特征及预后的相关性研究[J].现代检验医学杂志,2022,37(03):43-46.[doi:10.3969/j.issn.1671-7414.2022.03.009]
　LIU Xiao-xin,BAI Chun-xia,FU Yu.Expression of MAL2 and IGF-1R Protein in Breast Cancer and Its Correlation with Pathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(03):43-46.[doi:10.3969/j.issn.1671-7414.2022.03.009]
点击复制

乳腺癌组织MAL2和IGF-1R蛋白表达与病理特征及预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
43-46
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

Title:
Expression of MAL2 and IGF-1R Protein in Breast Cancer and Its Correlation with Pathological Features and Prognosis
文章编号:
1671-7414（2022）03-043-05
作者:
刘晓鑫; 白春峡; 伏　玉
（营口市中心医院 ，辽宁营口 115000）
Author(s):
LIU Xiao-xin;  BAI Chun-xia;  FU Yu
（the Center Hospital of Yingkou City，Liaoning Yingkou 115000，China）
关键词:
T 细胞分化蛋白2; 胰岛素样生长因子1 受体; 乳腺癌; 病理特点
分类号:
R737.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.03.009
文献标志码:
A
摘要:
目的　探讨乳腺癌组织 T细胞分化蛋白 2（mal T-cell di.erentiation protein 2，MAL2）、胰岛素样生长因子 1受体（ insulin like growth factor 1 receptor，IGF-1R）蛋白表达与病理特征及预后的相关性。方法　选取营口市中心医院 2015年 3月～ 2016年 3月收治的 131例乳腺癌患者，采用免疫组织化学法检测乳腺癌患者癌旁正常组织和癌组织 MAL2和 IGF-1R蛋白表达水平，分析 MAL2和 IGF-1R蛋白水平与不同病理特点及预后的关系，并采用 COX比例风险回归模型分析乳腺癌患者预后影响因素。结果　乳腺癌患者癌组织 MAL2（77.86%），IGF-1R蛋白（ 80.15% )阳性率显著高于癌旁正常组织 (17.56%，21.37%），差异有统计学意义（ χ2=95.482，90.540，均 P<0.05）；在不同乳腺癌 TMN分期以及分化程度上 MAL2和 IGF-1R蛋白阳性表达率差异均有统计学意义（ χ2 MAL2=33.545，16.188，χ2IGF-1R=6.533， 12.422，均 P＜ 0.001）。131例乳腺癌患者随访期间，预后较差患者 59例，预后良好患者 72例；预后较差组患者 MAL2（94.92%），IGF-1R（91.53%）蛋白阳性表达率显著高于预后良好组（ 36.11%，41.67%），差异均有统计学意义（χ2=18.110，8.727，均 P<0.05）。中低分化、 III～ IV期、MAL2蛋白阳性表达和 IGF-1R蛋白阳性表达是患者不良预后的危险因素（ P<0.05）。结论　MAL2和 IGF-1R蛋白在乳腺癌组织中具有较高的表达水平，且与乳腺癌患者 TMN分期和分化程度具有明显的相关性，可能是患者不良预后的危险因素之一。
Abstract:
Objective　To study the relationship between mal T cell differentiation protein 2 (MAL2) and insulin-like growth factor 1 receptor (IGF-1R) and the pathological characteristics and prognosis of breast cancer patients. Methods　131 patients with breast cancer admitted in the Center Hospital of Yingkou City from March 2015 to March 2016 were selected. The expression level of MAL2 and IGF-1R protein were detected by immunohistochemistry in the adjacent normal tissues and cancer tissues of breast cancer patients. The relationship between the level of MAL2 and IGF-1R protein and the pathological characteristics and prognosis of patients with breast cancer were analyzed. COX proportional hazards regression model was used to analyze the prognostic factors of breast cancer patients. Results　The positive rates of MAL2 (77.86%) and IGF-1R (80.15%) protein in breast cancer tissues were significantly higher than those in adjacent normal tissues (17.56%, 21.37%)?the differences were statistically significant（χ2=95.482，90.540，all P<0.05）.The positive rate of MAL2 and IGF-1R protein expression were statistically significant in TMN stage and differentiation degree of different breast cancer（χ2 MAL2 =33.545, 16.188, χ2 IGF-1R =6.533,12.422, all P ＜ 0.001). During the follow-up period of 131 cases of breast cancer, 59 patients with poor prognosis and 72 patientswith good prognosis, the MAL2 (94.92% ）and IGF-1R (91.53%）protein in the poor prognosis group were significantly higher than those in the good prognosis group (36.11%, 41.67%）, the differences were statistically significant(χ2=18.110, 8.727, all P<0.05）. Poor differentiation, stage III ～ IV, positive expression of MAL2 protein and IGF-1R protein were risk factors for poor prognosis (P<0.05). Conclusion　MAL2 and IGF-1R protein had high expression level in breast cancer, and they were significantly correlated with TMN stage and differentiation degree of breast cancer patients, At the same time, it may be one of the risk factors for the patient’s poor prognosis.

参考文献/References:

[1] 牛智平, 王娟, 汪富涛, 等. 乳腺癌组织中lncRNA PVT1的表达与患者临床特征及总体生存率的关系 [J]．现代检验医学杂志, 2020, 35 (5): 134-136. NIU Zhiping, WANG Juan, WANG Futao, et al. Relationship between the expression of lncRNA PVT1 in breast cancer tissues and the clinical characteristics and overall survival rate of patients [J]. Journal of Modern Laboratory Medicine, 2020, 35 (5): 134-136.
[2] 刘青, 张英, 周馨, 等.2009~2018 年北京地区单中 心乳腺癌临床流行病学及病理特征回顾性分析[J]. 肿瘤, 2020, 40(6):431-439. LIU Qing, ZHANG Ying, ZHOU Xin, et al. A single center,retrospective analysis on clinical epidemiology and pathologic characteristics of breast cancer in Beijing from 2009 to 2018 [J]. Tumor, 2020, 40 (6):431-439.
[3] 王苗. 外周血循环肿瘤细胞和肿瘤标志物在监测转 移性乳腺癌治疗及预后中的价值[J]. 实用癌症杂志, 2019, 34(1):79-81. WANG Miao. The value of detection of peripheral blood circulating tumor cells and tumor markers in the treatment and prognosis of metastatic breast cancer [J]. The Practical Journal of Cancer, 2019, 34 (1): 79-81.
[4] FANG Yuanzhang, WANG Lifei, WAN Changlin, et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation[J]. The Journal of Clinical Investigation, 2021, 131(1): e140837.
[5] 梅琳琳, 田晓娜, 燕旭靖. 卵巢癌中胰岛素样生长因 子-1 及其受体表达与临床病理特征的相关性[J]. 中 华内分泌外科杂志, 2020, 14 (1): 67-71. MEI Linlin,ZHOU Xiaona,YAN Xujing. Correlation of insulin-like growth factor-1 and its receptor in ovarian cancer with clinicopathological features [J]. Chinese Journal of Endocrine Surgery, 2020, 14 (1): 67-71.
[6] 曹泽毅. 中华妇产科学[M]．北京：人民卫生出版社, 2014. CAO Zeyi. Chinese obstetrics and gynecology [M]. Beijing：People’s Health Publishing House, 2014.
[7] 吴春晓, 顾凯, 王春芳, 等. 上海市女性乳腺癌流行 现况、回顾与比较分析[J]. 外科理论与实践, 2019, 24(5): 421-427. WU Chunxiao,GU Kai,WANG Chunfang,et al. Incidence of female breast cancer in Shanghai:current evidence and a comparative retrospective study [J]. Journal of Surgery Concepts & Practice , 2019, 24 (5): 421-427.
[8] 陈倩欣, 张怡心, 李科, 等. 广州市2008-2017 年全 人群女性乳腺癌特征及其与预后的关系[J]. 中华流 行病学杂志, 2020, 41(11):1831-1835. CHEN Qianxin,ZHANG Yi x i n , L I K e , e t a l . Characteristics and prognosis of female breast cancer in Guangzhou, 2008~ 2017[J]. Chinese Journal of Epidemiology , 2020, 41 (11): 1831-1835.
[9] 钱俊华, 王莹莹, 杨艳蕾, 等. 江苏省海门市1999- 2016 年成年女性乳腺癌发病及死亡趋势分析[J]. 中 华疾病控制杂志, 2020, 24 (2): 189-193,209. QIAN Junhua,WANG Yingying,YANG Yanlei,et al. Analysis on incidence and death trend of breast cancer in adult women from 1999 to 2016 in Haimen,Jiangsu Province [J]. Chinese Journal of Disease Control & Prevention, 2020, 24 (2): 189-193,209.
[10] 樊弘, 周礼平, 蒙荣钦. 彩色多普勒超声成像在乳腺 癌诊断及化疗效果评估中的意义[J]．实用癌症杂志, 2019, 34 (3): 497-499, 503. FAN Hong,ZHOU Liping,MENG Rongqin. Significance of color Doppler ultrasonography in breast cancer diagnosis and chemotherapy evaluation [J]. The Practical Journal of Cancer , 2019, 34 (3): 497-499, 503.
[11] 杨红波, 杜志权, 马立岩, 等. 动态增强MRI 与乳腺 DR 钼靶对致密型乳腺T1 及Tis 期乳腺癌诊断的价 值分析[J]．中国CT 和MRI 杂志, 2021, 135（1）： 101-103． YANG Hongbo, DU Zhiquan, MA Liyan, et al. Value of dynamic enhanced MRI and breast DR mammography in the diagnosis of dense breast cancer in T1 and Tis phases [J]. Chinese Journal of CT and MRI , 2021, 135 (1): 101-103.
[12] MUKHERJEE S, SEN S, ADHIKARY S, et al. A novel role of tumor suppressor ZMYND8 in inducing differentiation of breast cancer cells through its dualhistone binding function[J]. Journal of Biosciences, 2020, 45(1): 2.PMID:31965980.
[13] GUO Ling, ZHU Ye, LI Liandi, et al. Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1[J]. Cancer Medicine, 2019, 8(12): 5687-5701.
[14] YU Bowen, YUAN BO, KIYOMI A, et al. Differentiation induction of human breast cancer cells by arsenite in combination with tetrandrine[J]. American Journal of Translational Research, 2019, 11(12): 7310-7323.
[15] 周琪, 刘昊, 都一鸣, 等. MiR-195 通过下调IGF-1R 的表达抑制胶质母细胞瘤的增殖和迁移[J]. 现代生 物医学进展, 2019, 19 (20): 3807-3811． ZHOU Qi, LIU Hao,DU Yiming, et al. MiR-195 inhibits the proliferation and migration of glioblastoma through down-regulation the expression of IGF-1R[J]. Progress in Modern Biomedicine , 2019, 19 (20): 3807-3811．
[16] 李丹娟, 陈玮, 周兴平, 等. 绝经后乳腺癌与血清性 激素及胰岛素样生长因子的相关性研究[J]. 中国妇 幼保健, 2020, 35 (23): 4456-4458. LI Danjuan, CHEN Wei, ZHOU Xingping, et al.Correlation between serum levels of sex hormones and insulin-like growth factors in postmenopausal women with breast cancer [J]. Maternal & Child Health Care of China, 2020, 35 (23): 4456-4458.
[17] 刘晓伟, 张宏．胰岛素样生长因子1 受体在乳腺癌 组织中的表达及其意义[J]. 内蒙古医科大学学报, 2019, 41(4): 368-369, 373. LIU Xiaowei, ZHANG Hong.Expression of insulinlike growth factor 1 receptor in breast cancer and its significance [J]. Journal of Inner Mongolia Medical University, 2019, 41 (4):368-369, 373.
[18] 王宏, 王庚, 田文玲.miR-126 靶向胰岛素样生长因 子1 受体抑制胃癌增殖与侵袭的机制[J]. 中华肿瘤 杂志, 2019, 41 (7): 508-515. WANG Hong, WANG Geng, TIAN Wenling. MiR-126 inhibits the proliferation and invasion of gastric cancer by downregulation of IGF-1R [J].Chinese Journal of Oncology, 2019, 41 (7): 508-515.
[19] 张瑞敏, 芦晓, 晏妮. 宫颈癌患者血清胰岛素样生长 因子1, 基质金属蛋白酶9 的水平及临床意义[J]. 癌 症进展, 2019,17 (18): 2204-2206,2226. ZHANG Ruimin, LU Xiao, YAN Ni. Serum levels of insulin-like growth factor 1 and matrix metalloproteinase 9 in patients with cervical cancer and their clinical significance [J]. Oncology Progress, 2019,17 (18): 2204-2206,2226.
[20] 谭生权, 张碧涛, 孙建华. 血清胰岛素样生长因子1 与E- 钙黏蛋白在胃癌患者中的表达及临床意义[J]. 中华实用诊断与治疗杂志, 2019,33 (5):467-470． TAN Shengquan,ZHANG Bitao, SUN Jianhua. Expressions and clinical significances of insulin-like growth factor 1 and E-cadherin in gastric cancer [J]. Journal of Chinese Practical Diagnosis and Therapy, 2019,33 (5):467-470．

备注/Memo

备注/Memo:
基金项目：辽宁省自然科学基金项目（20150540957）。
作者简介：刘晓鑫（1989-），女，本科，主治医师，研究方向：肿瘤病理,E-mail：1592899@qq.com。
更新日期/Last Update: 1900-01-01